ArticleCancer reports (Hoboken, N.J.)2026
The Role of RANBP3L in Pan-Cancer With Its Significance in Hepatocellular Carcinoma.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of RANBP3L in Pan-Cancer With Its Significance in Hepatocellular Carcinoma.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRAN binding protein 3-like (RANBP3L), a member of the Ran-binding protein family, has been linked to various cellular functions, but the role in cancer remains underexplored. In this research, we assessed the diagnostic and prognostic value of RANBP3L in pan-cancer, especially in liver hepatocellular carcinoma (LIHC).
aimsThis study aimed to explore the pan-cancer expression, prognostic value, and immune-related roles of RANBP3L, especially emphasis on validating its diagnostic and prognostic significance in hepatocellular carcinoma.
methodsWe analyzed RANBP3L expression of 33 cancer types from TCGA data and assessed its relationship with overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). We used TIMER2.0 and CIBERSORT to explore the correlation between RANBP3L expression and immune cells. We conducted immunohistochemistry, qRT-PCR, and western blotting by using tissue samples from LIHC patients to assess the RANBP3L's diagnostic and prognostic value of LIHC.
resultsIn 18 different cancers, RANBP3L expression was found to be lower in tumor tissues compared to normal tissues, including LIHC. Lower RANBP3L expression was related to shorter OS, DSS, and PFI in LIHC. ROC analysis and the nomogram model based on RANBP3L expression demonstrated high predictive accuracy for patient diagnosis and survival. Moreover, immune infiltration analysis showed that RANBP3L was related to various immune cells and impacted prognosis. Furthermore, analysis of LIHC patient tissues found that higher RANBP3L expression was related to better tumor-free survival and OS.
conclusionRANBP3L plays a crucial role in LIHC. Not only does its expression level correlate with patient survival, but it also plays an important role in immune modulation. RANBP3L presents a promising candidate for future therapeutic strategies and a biomarker for LIHC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.